Apuntes para una estrategia de medicamentos “esenciales” para Latinoamérica

Gianni Tognoni Dipartimento di Ricerca Cardiovascolare, IRCCS Istituto di Ricerche Farmacologiche “Mario Negri.” Milano, Italy. image/svg+xml
Recibido: 5 agosto 2016, Aceptado: , Publicado: 4 octubre 2016 Open Access
Vistas de resumen
740
Cargando métricas ...

Palabras clave: Medicamentos


Referencias bibliográficas


1. Gray AL, Wirtz VJ, 't Hoen EF, Reich MR, Hogerzeil HV. Essential medicines are still essential. Lancet. 2015;386:1601-1603.

2. Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. New England Journal of Medicine. 2016;374:194-197.

3. Niessen LW, Khan JAM. Universal access to medicines. Lancet. 2016;387: 9-11.

4. Schroeder LF, Guarner J, Elbireer A, Castle PE, Amukele TK. Time for a model list of essential diagnostics. New England Journal of Medicine. 2016;374:2511-2514.

5. Gotham D, Onarheim KH, Barber MJ. How the MDGs gave up on measuring access to medicines. Lancet Global Health. 2016;4(5):e296-e297.

6. World Health Organization. The selection of essential drugs: Report of a WHO Expert Committee (WHO Technical Report Series, No. 615). Geneva: WHO; 1977.

7. Declaration of Alma-Ata. International Conference on Primary Health Care, Alma-Ata, USSR, 6-12 September 1978 [Internet]. WHO [citado 20 jul 2016]. Disponible en: http://goo.gl/FJBEfZ

8. Commission on Social Determinants of Health. Closing the gap in a generation: health equity through action on the social determinants of health: Final Report of the Commission on Social Determinants of Health [Internet]. Geneva: WHO; 2008 [citado 20 jul 2016]. Disponible en: http://goo.gl/Nd7eeO.

9. United Nations. Sustainable Development Goals [Internet]. UN, Department of Economic and Social Affairs [citado 15 jul 2016]. Disponible en: https://goo.gl/sRozSM

10. Zubizarreta JH. El TTIP, TPP, TISA, CETA...vulneran el sistema internacional de los derechos humanos [Internet]. América Latina en Movimiento; 04 ene 2016 [citado 15 jul 2015]. Disponible en: http://goo.gl/J6KKc5

11. Baker BK. Trans-Pacific partnership provisions in intellectual property, transparency, and investment chapters threaten access to medicines in the US and elsewhere. PLoS Medicine. 2016;13(3):e1001970.

12. Lo S, Horton R. Everyone counts-so count everyone. Lancet. 2015;386:1313-1314.

13. Price JA, Guinness L, Irava W, Khan I, Asante A, Wiseman V. How to do (or not to do)... translation of national health accounts data to evidence for policy making in a low resourced setting. Health Policy and Planning. 2016;31:472-481.

14. Sidibè M. Universal health coverage: political courage to leave no one behind. Lancet Global Health. 2016;4(6):e355-e356.

15. Bárcena A. Health protection as a citizen's right. Lancet. 2015;385:e29-e30.

16. Mandeville KL, Lagarde M, Hanson K, Mills A. Human resources for health: time to move out of crisis mode. Lancet. 2016;388:220-222.

17. Human resources for health-investing in action. Lancet. 2016;387:1591.

18. No health workforce, no global health security. Lancet 2016;387:2063.

19. Rescala Nemtala T, Tognoni G, (eds). Salud como derecho humano y de los pueblos. La Paz: Universidad Mayor de San Andrés, Università degli Studi di Torino; Stigma Editores; 2013.

20. Khoury MJ, Gwinn M, Ioannidis JPA. The emergence of translational epidemiology: from scientific discovery to population health impact. American Journal of Epidemiology. 2010;172:517-524.

21. Vargas I, Mogollón-Pérez AS, De Paepe P, Ferreira da Silva MR, Unger JP, Vásquez ML. Barriers to healthcare coordination in market-based and decentralized public health systems: a qualitative study in healthcare networks of Colombia and Brazil. Health Policy and Planning. 2016;31:736-748.

22. Confortini CC, Krong B. Breast cancer in the global south and limitations of a biomedical framing: a critical review of the literature. Health Policy and Planning. 2015;30:1350-1361.

23. van Staa TP, Goldacre B, Buchan I, Smeeth L. Big health data: the need to earn public trust. BMJ. 2016;354:i3636. doi: 10.1136/bmj.i3636.

24. Ioannidis JPA. Why most clinical research is not useful. PLoS Medicine. 2016;13(6):e1002049. doi:10.1371/journal.pmed.1002049.

25. Bastian H. Nondisclosure of financial interest in clinical practice guideline development: An intractable problem? PLoS Medicine. 2016;13(5):e1002030.

26. Hey SP, Kesselheim AS. Countering imprecision in precision medicine: Better coordination is needed to study complex interventions. Science. 2016;353:448-449.

27. Vouching for access. Nature Medicine. 2016;22:693.

28. Hotez PJ, Peiperl L. Noncommunicable diseases: a globalization of disparity? PLoS Medicine. 2015;12(7):e1001859.

29. van de Vijver S, Oti S, Oduor C, Ezeh A, Lange J, Agyemang C, Kyobutungi C. Challenges of health programmes in slums. Lancet. 2015;368:2114-2116.

30. Chan C, Mandeville KL. Improving access to NCD medicines through collaboration. Lancet. 2016;387:1704-1705.

31. Merson L, Gaye O, Guerin PJ. Avoiding data dumpsters - toward equitable and useful data sharing. New England Journal of Medicine. 2016;374:2414-2415.

32. Goenka S, Andersen LB. Our health is a function of where we live. Lancet. 2016;387:2168-2170.

33. Buse K, Howkes S. Sitting on the FENSA: WHO engagement with industry. Lancet. 2016;388:446-447.